Abstract: Objective To assess antituberculosis efficacy,suitable dose and application perspective of levofloxacin in China.Methods 97 new smear positive pulmonary tuberculosis patients were randomly allocated into treatment group(50 cases,receiving 2HL 2V/4HL 2 regimen)and controls(47 cases,2HL 2Z/4HL 2)for observation.Results The sputum negative conversion rates at the 2nd month in treatment group and the controls were 94.0% and 83.0% respectively,and at the end of chemotheraphy 98.0% and 97.7% Chest radiography showed remarkable improvement.The resolution of pulmonany lesions in the treatment group and the controls accounted for 98.0% and 95.7% respectively,with cavity closure rates of 73.1% in the treatment group and 50.0% in the controls.The drug adverse reaction rates were 13.2% in the treatment group and 7.8% in the controls.Conclusion Levofloxacin is a new effeitive and safety antituberculosis drug.

Key words: Tuberculosis, pulmonany, Drug therapy, Levofloxacin